Systemic light chain amyloidosis and Sjogren syndrome: An uncommon association

Amyloid

Volumn 16, Issue 3, 2009, Pages 181-182

  Perlat, Antoinette ^a   Decaux, Olivier ^a   Gervais, Renaud ^b   Rioux, Nathalie ^b   Grosbois, Bernard ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Amyloidosis; Heart failure; Sjogren syndrome

Indexed keywords

AMYLOID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GADOLINIUM CHLORIDE; MELPHALAN; THALIDOMIDE;

AGED; AMYLOIDOSIS; ARTICLE; BONE MARROW BIOPSY; BRADYCARDIA; CASE REPORT; CHRONIC WASTING DISEASE; CLAUDICATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; ECHOGRAPHY; ELECTROCARDIOGRAM; FEMALE; GLOSSODYNIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HOSPITAL ADMISSION; HUMAN; HYPOKINESIA; IMMUNOPHENOTYPING; LIGHT CHAIN; LOWER LIP; MACROGLOSSIA; MONOCLONAL IMMUNOGLOBULINEMIA; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PLASMA CELL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SALIVARY GLAND BIOPSY; SCHIRMER TEST; SJOEGREN SYNDROME; SYSTEMIC LIGHT CHAIN AMYLOIDOSIS; TREATMENT OUTCOME; XEROSTOMIA;

AGED; AMYLOIDOSIS; ANTIBODIES; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; SJOGREN'S SYNDROME;

EID: 70849111546     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120903090692     Document Type: Article

References (8)

1. Grosbois B, Jego P, Leblay R. Gougerot-Sjogren syndrome and malignant lymphoproliferative syndromes. Rev Med Interne 1998;19:319-324.
2. Palladini G, Perfetti V, Perlini S, Obici L, lavatelli F, Caccialanza R, Invernizzi R, Comotti B,Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103: 2936-2938.
3. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic A amyloidosis. Blood 2007;109:457-464.
4. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, AlexanderE, Carsons S, Daniels T, Fox P, Fox R, Kassan S, Pillemer S, Talal N, Weisman M. European Study Group on Classification Criteria for Sjögren's syndrome; Classification criteria for Sjögren syndrome: Arevised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
5. Meijer JM, Schonland SO, Palladini G, Merlini G, Hegenbart U, Ciocca O, Perfetti V, Leijsma MK, Bootsma H, Hazenberg BP. Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? Arthritis Rheum 2008;58:1992-1999.
6. Delèvaux I, André M, Amoura Z, Kemeny JL, Piette JC, Aumaître O. Concomitant diagnosis of primary Sjögren's syndrome and systemic AL amyloidosis. Ann Rheum Dis 2001;60:694-695.
7. Itoh T, Ohashi S, Tsujino T, Takenaka M, Kodama H, Kishihara M, Inatome T, Inoh T. Primary amyloidosis with dry eyes and dry mouth -a case report. Jpn J Med 1991;30:597-599.
8. Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, Connors LH, Skinner M, Seldin DC. Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinicalpresentation, molecular features, and survival. Arthritis Rheum 2007;56: 3858-3868.